More interestingly, a recent report found that co-inhibition of IL-13 and transforming growth factor-β (TGF-β) signaling attenuate the fibrotic machinery more completely than inhibiting TGF-β alone in NAFLD-associated fibrosis [6]. This evidence concerns the gene IL13 and metabolic dysfunction-associated steatotic liver disease.